MAM
Ashish Bhasin hands over charge of AAAI to Anupriya Acharya
NEW DELHI: Ashish Bhasin, president of Advertising Agencies Association of India( AAAI) has handed over charge of AAAI to Publicis Groupe’s CEO south Asia, Anupriya Acharya, who was elected as the president of Advertising Agencies Association of India (AAAI) for the year 2020-21 at its Annual General Body Meeting held recently.
GroupM CEO south Asia Prasanth Kumar was unanimously elected VP of the association.
Other elected members of the Executive Committee in alphabetical order are:
Anand Bhadkamkar Dentsu Aegis Network Marketing Solutions Pvt Ltd
Kunal Lalani Crayons Advertising Pvt Ltd
Mohit Joshi Havas Media India Pvt Ltd
Pranav Premnarayen Prem Associates Advertising & Marketing
Rana Barua Havas Worldwide India Pvt Ltd
Vivek Srivastava Innocean Worldwide Communications Pvt Ltd
Ashish Bhasin will be the ex-officio member of the AAAI Executive Committee for 2020-21 as its immediate past President.
Acharya said “It’s a tremendous honor and also an enormous responsibility to be elected as the President of such a prestigious organisation. I am acutely aware that our industry, like the rest of the world, has just witnessed the most unprecedented times and it’s a difficult time for most. The pandemic has only underscored the relevance of collective thinking and the heightened role that AAAI can play. I will strive to do my best to further the interests of the advertising industry and take AAAI to greater heights as we emerge into the new normal. Many top advertising professionals have contributed very selflessly and relentlessly to the AAAI, both with and without executive positions. And that is what inspires me immensely as I take on this position. Many thanks to Ashish Bhasin for his leadership in the last two years as President – he has made great progress in making the association more inclusive, diverse, and future-ready. Also, thanks to all the Executive committee members and the secretariat for all the learning they have given me in the past many years”.
Bhasin stated, “I have had the privilege to lead AAAI for two years as its president, I wish to thank all my fellow executive committee members for their wholehearted cooperation and valuable support. I would also like to congratulate Anupriya Acharya on her election as President. Anupriya has been a key member of the Indian media and advertising industry for a long time. I’m sure she will play a stellar role in taking forward the Association and its work. I wish her the very best for this role.”
The Advertising Agencies Association of India (AAAI) is the apex national organisation of advertising agencies, formed in 1945, to promote their industry interests so that they continue to make an essential and ever-increasing contribution to the nation. The AAAI today is truly representative, with a large number of small, medium, and large-sized agencies as its members, who together account for almost 80% of the advertising business placed in the country.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
